Equities

GemPharmatech Co Ltd

688046:SHH

GemPharmatech Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)11.43
  • Today's Change-0.05 / -0.44%
  • Shares traded2.98m
  • 1 Year change-53.27%
  • Beta--
Data delayed at least 15 minutes, as of Apr 18 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

GemPharmatech Co Ltd, formerly Jiangsu Jicui Yaokang Biotechnology Co Ltd, is a China-based company principally engaged in the research, development, production and sales of experimental mouse models. The Company uses gene-editing and other technologies to produce mouse models. The Company also involves in the business of customized model breeding, drug efficacy analysis, and model customization. The Company’s products are mainly used to satisfy the experimental demands in the fields of gene function cognition, disease mechanisms analysis, drug target discovery, and other fundamental researches.

  • Revenue in CNY (TTM)584.83m
  • Net income in CNY154.23m
  • Incorporated2017
  • Employees1.34k
  • Location
    GemPharmatech Co LtdNo. 12 Xuefu Road, Jiangbei New AreaNANJING 210061ChinaCHN
  • Phone+86 2 558265927
  • Fax+86 2 558265927
  • Websitehttps://www.gempharmatech.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Innovita Biological Technology Co Ltd625.12m266.22m4.53bn404.0017.032.28--7.251.961.964.5914.620.30931.676.231,547,324.0013.17--14.20--80.99--42.59--10.66--0.0015--7.03--15.44------
Shanghai Haoyuan Chemexpress Co Ltd1.76bn153.96m4.54bn3.37k29.261.84--2.571.031.0311.8516.400.51050.96354.23523,753.404.41--5.76--47.63--8.64--0.849417.190.299--40.12--1.39------
Shanghai Medicilon Inc1.60bn175.05m4.59bn3.11k23.911.72--2.871.431.4313.2119.850.56065.722.39485,695.906.1314.507.8917.9731.2641.2510.9320.812.6738.480.154318.0242.1246.0919.8552.0546.98--
Beijing Konruns Pharmaceutical Co Ltd998.77m146.45m4.60bn449.0030.731.44--4.610.93590.93596.3820.020.28032.953.932,224,437.004.836.365.557.2787.9891.2717.2421.974.8915.470.039722.357.037.97-31.42-26.6823.35--
HitGen Inc357.22m33.12m4.63bn508.00139.093.46--12.960.0830.0830.8953.340.21196.883.38703,184.901.985.872.116.5948.3664.419.3424.4816.24--0.151112.605.9844.01-60.14--47.85--
Hunan Fangsheng Pharmaceutical Co Ltd1.65bn168.39m4.65bn1.60k27.183.26--2.820.38920.38923.803.240.5791.657.071,030,799.006.195.2110.338.7966.9767.7310.698.240.673423.210.345642.5814.3619.98308.1236.795.21103.62
GemPharmatech Co Ltd584.83m154.23m4.71bn1.34k30.522.26--8.050.37620.37621.435.080.25013.782.48435,790.406.60--7.40--68.05--26.37--5.12--0.0553--31.17--31.79------
Yabao Pharmaceutical Group Co Ltd2.94bn211.62m4.76bn4.37k22.491.56--1.620.27480.27483.823.950.73063.106.61674,351.305.203.226.794.7055.2259.727.124.931.6815.300.088466.95-1.661.22-44.06-12.17-8.93-12.94
Shanghai Haixin Group Co Ltd1.34bn119.74m4.85bn849.0053.541.60--3.620.09920.09921.113.320.26779.187.541,575,839.002.972.563.402.9340.8343.4011.0810.732.27--0.010829.50-4.717.5624.209.27-28.548.45
Data as of Apr 18 2024. Currency figures normalised to GemPharmatech Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

4.78%Per cent of shares held by top holders
HolderShares% Held
GF Fund Management Co., Ltd.as of 30 Jun 20231.71m1.15%
China Universal Asset Management Co., Ltd.as of 30 Jun 20231.29m0.87%
Wanjia Asset Management Co., Ltd.as of 30 Jun 2023796.13k0.54%
Hongde Fund Management Co., Ltd.as of 30 Jun 2023686.00k0.46%
Everbright PGIM Fund Management Co. Ltd.as of 30 Jun 2023635.18k0.43%
New China Fund Management Co., Ltd.as of 30 Jun 2023631.02k0.43%
Premia Partners Co. Ltd.as of 03 Apr 2024365.56k0.25%
Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 2023355.97k0.24%
Golden Trust Sinopac Fund Management Co., Ltd.as of 30 Jun 2023346.70k0.23%
Guotai Asset Management Co., Ltd.as of 30 Jun 2023283.44k0.19%
More ▼
Data from 30 Jun 2023 - 03 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.